IRF4 and inflammatory bowel disease: Theoretically, DC-specific activation of IRF4 is assumed to inhibit the development of IBD by downregulating proinflammatory cytokine responses against TLR ligands derived from intestinal bacteria (27–29, 35, 51, 52).